CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

  • Marcus P. Watkins, Nancy L. Bartlett
  • Expert Opinion on Investigational Drugs, July 2018, Taylor & Francis
  • DOI: 10.1080/13543784.2018.1492549

New CD19-targeted treatment for patients non-Hodgkin B-cell lymphomas

What is it about?

Expression of CD19 on B cell non-Hodgkin lymphoma has identified it as a potential target for immune-based therapies. Various types of CD19 targeted treatments are reviewed and discussed

Why is it important?

Targeted treatments for non-Hodgkin lymphoma often reduce the off-target side effects of conventional chemotherapy, but may cause other unexpected side-effects. These are discussed in this review.

Perspectives

Dr. Marcus Watkins
Washington University in Saint Louis

Some CD19 targeting therapies in particular chimeric antigen receptor (CAR) modified T cells have impressive responses in relapsed NHL patients. CAR-T cells therapies are the most promising, with the potential for curing a third of refractory diffuse large B cell NHL patients. If the promise of CAR-T cell technology is confirmed, this will likely change the approach and prognosis for relapse/refractory aggressive lymphoma

Read Publication

http://dx.doi.org/10.1080/13543784.2018.1492549

The following have contributed to this page: Dr. Marcus Watkins